Sun Pharma signs US deal to offer 'most favoured nation' pricing on drugs

•Sun Pharma signed a US deal to offer 'most favoured nation' pricing on drugs, prioritizing access to affordable medicines for American patients.

•The agreement, signed at the White House, applies to state Medicaid programmes and future innovative medicine launches in the US market.

•Sun Pharma's investment in the US is recognized, delaying Section 232 tariffs on its innovative pharmaceutical products for over two years.

•The deal is part of Sun Pharma's expansion in the US, where it is the largest market for innovative medicines, contributing 27% of total global revenue.